Design and rationale for MAGNITUDE, a phase 3, randomized, placebo-controlled trial of NTLA2001, a CRISPR-based gene editing therapy, in patients with transthyretin amyloidosis with cardiomyopathy (ATTR- CM) - Maurer, Mathew S; Fontana, Marianna; Claggett, Brian; Hernandez, Adrian; Januzzi, James L; Lam, Carolyn; Lewis, Eldrin; Garcia-Pavia, Pablo; Shah, Sanjiv J; Solomon, Scott; Gutstein, David; Pickard, Michael D; et al. (Amyloid-Journal Of Protein Folding Disorders, 2024)